Hummingbird Bioscience and Cancer Research UK have dosed the first subject in a Phase I trial of the company’s monoclonal antibody drug candidate, HMBD-001, to treat individuals with advanced HER3-expressing solid malignancies in the UK.

An anti-HER3 antibody, HMBD-001 leverages a differentiated mechanism of action to potentially hinder the development of all active HER3 dimers, irrespective of NRG1 ligand binding or overexpression of HER2/EGFR.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The trial is sponsored and run by the Centre for Drug Development of the Cancer Research UK and The Institute of Cancer Research, London.

It will analyse the safety, tolerability, pharmacodynamics, pharmacokinetics and detect initial evidence of the antibody’s activity in subjects with advanced HER3-expressing solid malignancies, comprising NRG1 fusion-driven tumours.

Hummingbird Bioscience chief scientific officer Dr Jerome Boyd-Kirkup said: “Dosing of the first patient in the clinical trial of HMBD-001, Hummingbird’s most advanced programme, marks the beginning of a potentially transformative approach to treating HER3-driven cancers.

“Hummingbird Bioscience is dedicated to discovering and developing important medicines for cancer and autoimmune disease with our unique Rational Antibody Discovery platform.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Preliminary results from the Phase I dose-escalation trial are anticipated in the second half of next year.

In preclinical models, HMBD-001 showed greater affinity and potently hindered tumour growth versus other current anti-HER3 antibodies.

Cancer Research UK Centre for Drug Development director Dr Nigel Blackburn said: “Although HER3 was discovered over 30 years ago, no therapies able to block its cancer-promoting action have been approved.

“Hummingbird Bioscience has taken fresh aim at a difficult drug target and has come up with a novel, potentially transformative antibody for cancer patients who desperately need new treatments.”

In August 2019, Hummingbird and Cancer Research UK partnered to develop HMBD-001 for the treatment of HER3-driven cancer patients.